<DOC>
	<DOCNO>NCT00302250</DOCNO>
	<brief_summary>The primary objective double-blind segment compare effect alagebrium vs placebo change baseline endothelial function , assess flow-mediated vasodilation ( FMD ) .</brief_summary>
	<brief_title>The STRETCH Study : Distensibility Endothelial-Dependent Vasoreactivity Subjects With Systolic Hypertension</brief_title>
	<detailed_description>The secondary objective double-blind segment : - Compare effect alagebrium vs placebo change baseline endothelial-mediated vasoreactivity immediately exercise , assess pulse perfusion-mediated vasodilation ( PPMV ) . - Confirm result observe single-blind segment . - Explore several variable potential independent predictor vascular stiffness endothelial function . These parameter include age , body mass index , gender , renal disease , history cardiovascular disease , serum cholesterol , antihypertensive medication use . - Provide insight nitric oxide-dependent endothelial function set increase arterial stiffness determination substance nitric oxide signal pathway ( specifically , level serum cGMP ; serum nitrate nitrite ; serum asymmetric dimethylarginine [ ADMA ] , endogenous inhibitor nitric oxide synthase ) . - Provide insight relationship AGE level ( AGE marker : pentosidine , furosine ) , collagen metabolism ( collagen marker : procollagen I carboxyterminal propeptide [ PICP ] , procollagen type I N terminal propeptide [ PINP ] , cross-linked carboxyterminal telopeptide Type I collagen [ ICTP ] , n-terminal propeptide type III procollagen [ PIIINP ] ) , endothelial function ; insight change marker response treatment AGE cross-link breaker ( alagebrium ) . - Provide insight relationship marker inflammation [ specifically , free total serum matrix metalloproteinase-1 ( MMP-1 ) , free tissue inhibitor metalloproteinase 1 ( TIMP1 ) , intercellular adhesion molecule-1 ( ICAM ) , vascular cellular adhesion molecule ( VCAM ) , P-selectin , von Willebrand factor ( vWf ) , interleukin-6 ( IL-6 ) , endothelin 1 , VEGF , NFkβ , TGF-β , IGF-1 high-sensitivity C reactive protein ( hs CRP ) ] endothelial function ; insight change marker response treatment AGE cross-link breaker ( alagebrium ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>1 . Male female 50 year age great . 2 . Diagnosed systolic hypertension ( systolic blood pressure &gt; 140 mm Hg ( less equal ) 200 mm Hg , diastolic blood pressure ( less equal ) 95 mm Hg ) elevate pulse pressure ( systolic blood pressure [ SBP ] minus diastolic blood pressure [ DBP ] great 60 mm Hg ) . 3 . Normal leave ventricular function ( ejection fraction &gt; 55 % ) baseline ( Visit 3 ) . 4 . Brachial artery must able visualized FMD PPMV determination . 5 . Able perform bicycle exercise . 6 . Able read , understand sign inform consent nature study explain . 7 . If sexually active , subject agrees use reliable contraception participate study . If woman , surgically sterilize postmenopausal , negative serum pregnancy test . 1 . Aortic stenosis , prior know coronary artery disease ( include myocardial infarction ) , cerebrovascular accident , peripheral vascular disease . 2 . Uncontrolled hypertension ( SBP &gt; 200/DBP &gt; 95 mm Hg ) . 3 . Atrial fibrillation , diabetes mellitus treat insulin , chronic lung disease . 4 . Any additional condition ( ) , opinion investigator , would prohibit subject complete study , best interest subject . 5 . Treatment nitrate , change antihypertensive medication within last 1 month . 6 . Treatment investigational drug within 1 month prior study drug administration . 7 . Previous exposure alagebrium . 8 . AST ( SGOT ) ALT ( SGPT ) &gt; 2x normal limit . 9 . Serum creatinine &gt; 2.0 mg/dL . 10 . Cigar/cigarette smoking . 11 . Necessity use smokeless tobacco nicotinecontaining product , consume caffeine , alcohol , antioxidant start midnight prior study clinic visit . NOTE : Water allow ad libitim . 12 . Positive drug screen .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Cardiovascular</keyword>
	<keyword>Flow-mediated vasodilation ( FMD )</keyword>
	<keyword>Pulse perfusion-mediated vasodilation ( PPMV )</keyword>
	<keyword>Endothelial function</keyword>
	<keyword>Heart failure</keyword>
</DOC>